• News

  PHARMO Magazine

  Please find below our newest PHARMO Magazine. In our online magazine you can read more about, amongst other things,  our newest additions to the team, our collaboration with Germany and Italy on biologicals in colorectal cancer, data protection by S...

  PHARMO Magazine

  We are proud to offer you the first edition of our new and improved PHARMO Magazine. In this online magazine you can read about our research, our collaborations with universities and other research institutions and upcoming events. Through our st...

  PHARMO’s annual scientific report 2018 available

  PHARMO's annual scientific report discusses the current expertise and research of the PHARMO Institute, publications, international collaborations and partners. Furthermore the annual report describes the organisational structure and information on h...

• Events

• Vacancy

  Junior Onderzoeker

  Junior onderzoeker PHARMO is op zoek naar een junior onderzoeker ter ondersteuning van de afdeling Onderzoek. In je dagelijkse werk houd je je bezig met het in teamverband uitvoeren van analyses en (deel)opdrachten. Dit omvat onder andere statist...

• 

  What we do

  As an independent research organisation dedicated to the study of epidemiology, drug utilisation, drug safety, health outcomes, and utilisation of healthcare resources PHARMO assists its clients in their decision-making.

  Read more
• 

  What we have

  PHARMO Database Network: we have rapid access to our rich population-based network of databases. Data are derived from different primary and secondary healthcare settings. For our observational studies disease-specific cohorts are created from the various databases.

  Read more

Publications

• Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands

  Read more

• No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study

  Read more

• Trends in mortality, cardiovascular complications, and risk factors in type 2 diabetes

  Read more

• The risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depression

  Read more